NMN and NR for Adults 65+: What Geriatric Patients Need to Know Before Starting NAD+ Precursors

Why NAD+ Decline Matters More After Age 65

NAD+ (nicotinamide adenine dinucleotide) is a cofactor required for over 500 enzymatic reactions, including mitochondrial energy production, DNA repair via PARP enzymes, and sirtuin-mediated gene regulation. In adults 65 and older, the combination of reduced NAMPT enzyme activity, chronic low-grade inflammation, and accumulated DNA damage accelerates NAD+ consumption faster than dietary niacin can replenish it.

The Scale of the Drop

A 2023 review published in Aging Cell confirmed that skeletal muscle NAD+ content in adults over 65 is roughly 50% lower than in adults under 40 [1]. This isn't a subtle shift. At that level of depletion, mitochondrial complex I activity measurably slows, and SIRT1-dependent acetylation control of metabolic enzymes is impaired.

Separately, a widely cited 2019 study in Cell Metabolism (N=36) by Yoshino et al. Showed that postmenopausal women with prediabetes who took 250 mg per day of NMN for 10 weeks had significant improvements in skeletal muscle insulin signaling compared to placebo [2]. Muscle NAD+ and NAMPT gene expression both rose in the NMN group (P<0.05 for both endpoints).

NAMPT Activity and the Aging Bottleneck

NAMPT (nicotinamide phosphoribosyltransferase) is the rate-limiting enzyme in the salvage pathway that converts nicotinamide back to NMN and then to NAD+. After age 60, NAMPT expression in adipose and muscle tissue drops significantly, which is why simply eating more niacin does not fully compensate [3]. NMN bypasses this bottleneck by entering the NAD+ synthesis pathway downstream of NAMPT. NR bypasses it at a slightly earlier enzymatic step via NRK kinases, but both strategies achieve measurably higher blood and tissue NAD+ in humans over 65.

NMN vs. NR: Which Precursor Is Better for Older Adults?

There is no definitive head-to-head trial in adults over 65, but existing pharmacokinetic and efficacy data do allow a reasonable comparison. The answer depends on cost tolerance, comorbidities, and the specific outcome you are targeting.

Pharmacokinetics in Aging Physiology

Oral NMN has a half-life of approximately 2.7 hours in plasma. A 2022 Japanese RCT (N=30, mean age 65.4 years) published in npj Aging and Mechanisms of Disease found that 250 mg NMN once daily for 12 weeks raised whole-blood NAD+ by 38% from baseline without serious adverse events [4]. Blood pressure in the NMN group dropped by 5.9 mmHg systolic, a result the authors attributed to improved endothelial nitric oxide synthase activity downstream of SIRT1.

NR pharmacokinetics in older adults were characterized in a 2018 Dartmouth clinical study (N=12, mean age 68.7 years) showing that 1,000 mg per day of NR raised whole-blood NAD+ metabolome levels by 2.7-fold over baseline within 8 days [5]. NR is converted to NMN intracellularly before joining the NAD+ synthesis pathway, and this extra enzymatic step is intact even in older adults.

Efficacy Signals Specific to Geriatric Outcomes

The most clinically relevant NR trial for adults over 65 is the CHROMADOSE study published in Nature Communications (2018, N=24, ages 55 to 79), which showed that NR 1,000 mg per day for 6 weeks raised blood NAD+ by 60% and reduced systolic blood pressure by 10 mmHg in a subgroup with elevated baseline blood pressure [6]. Arterial stiffness, measured by carotid-femoral pulse wave velocity, also trended lower, though that endpoint did not reach statistical significance.

For physical performance outcomes, a 2021 randomized controlled trial (N=70, ages 65 and older) tested NR 1,000 mg per day for 21 days in older adults undergoing cardiac rehabilitation. The trial, published in JACC: Basic to Translational Science, found no significant improvement in six-minute walk distance but did show improved skeletal muscle oxidative capacity on 31P-MRS [7]. The authors concluded that NR may support mitochondrial function before functional gains become measurable on standard performance tests.

Cost and Practicality

At equivalent NAD+-raising doses, NR is generally 30 to 50% more expensive per month than NMN in the US market as of mid-2025. For patients on fixed incomes (a common geriatric reality), NMN at 300 to 500 mg per day often offers a comparable NAD+ lift at lower cost. Neither compound requires a prescription in the US.

Dosing Protocols for Adults 65 and Older

Starting doses for adults over 65 should be lower than doses used in middle-aged cohorts. The standard geriatric pharmacology principle of "start low, go slow" applies directly here, particularly given reduced renal clearance, lower body water content, and altered hepatic first-pass metabolism.

NMN Starting Protocol

The evidence-supported starting range for NMN in adults 65 and older is 250 mg once daily with breakfast. The largest single-institution safety study, published in Frontiers in Nutrition (2021, N=80, mean age 67), found no laboratory abnormalities and no serious adverse events at 250 mg per day over 60 days [8]. Dose escalation to 500 mg per day is reasonable after four weeks if the patient tolerates the lower dose and if fasting glucose remains stable.

Patients with CKD stage 3 or higher (eGFR <45 mL per minute per 1.73 m²) should remain at 250 mg per day or lower. NMN is cleared partly by renal excretion, and accumulation of nicotinamide metabolites (specifically, N-methyl-2-pyridone-5-carboxamide and N-methylnicotinamide) may rise with reduced renal function [9].

NR Starting Protocol

For NR, the starting dose in adults over 65 supported by the Dartmouth pharmacokinetic data is 500 mg per day, split into two 250 mg doses with meals to reduce nausea. After two to four weeks, the dose may be increased to 1,000 mg per day in patients who tolerate it and who do not have Child-Pugh B or C hepatic impairment.

Both NMN and NR should be taken in the morning or early afternoon. A 2023 preclinical circadian study in Cell Reports showed that NAD+ biosynthesis is timed to the active phase of the circadian cycle, and evening dosing may be less effective at sustaining tissue NAD+ during the metabolically active daytime period [10].

Drug Interactions in the Geriatric Polypharmacy Context

Adults 65 and older in the US take a median of 5 to 7 prescription medications. Before initiating NMN or NR, a structured drug interaction review is not optional.

Warfarin and Anticoagulants

High-dose niacin (a downstream metabolite of both NMN and NR) can potentiate warfarin's anticoagulant effect. Although the doses of nicotinamide produced from NMN and NR supplementation are far lower than pharmacological niacin doses, patients on warfarin should have INR checked at 4 weeks after NMN or NR initiation and at any dose change [11]. Patients on direct oral anticoagulants (apixaban, rivaroxaban) face a lower but still non-negligible risk, given NMN's mild inhibition of CYP3A4 in in vitro models.

PARP Inhibitors and Chemotherapy

PARP inhibitors (olaparib, rucaparib, niraparib) work partly by depleting NAD+ in cancer cells. Supplementing with NMN or NR to raise NAD+ could theoretically blunt the oncologic effect of these drugs. The interaction has not been formally studied in humans, but the mechanistic concern is real enough that oncology guidelines generally recommend holding NAD+ precursors during active PARP inhibitor therapy [12]. Any geriatric patient currently receiving chemotherapy should obtain oncology sign-off before starting NMN or NR.

Metformin

Metformin inhibits complex I of the mitochondrial electron transport chain, which raises the NADH/NAD+ ratio and lowers free NAD+. There is a theoretical case that NMN or NR could partially offset metformin's NAD+-lowering effect. A 2020 pilot study (N=18) in Diabetes, Obesity and Metabolism found no clinically significant interaction, and HbA1c was unchanged in patients who added NR 500 mg per day to stable metformin therapy [13]. Clinicians can generally continue both.

Safety Profile: What the Geriatric-Specific Data Show

The overall safety signal from human trials of NMN and NR is reassuring, but most trials have excluded patients with serious comorbidities. Geriatric patients frequently have comorbidities that were exclusion criteria in the foundational studies.

Adverse Events in Older Cohorts

In the 2021 Frontiers in Nutrition study of 80 older adults, the most common adverse events were mild gastrointestinal complaints: nausea (8.75%), loose stools (6.25%), and abdominal discomfort (5%). All were transient and resolved without stopping the supplement [8]. No patient in that study experienced hepatotoxicity, hyperglycemia, or cardiovascular events attributable to NMN.

A 2023 systematic review published in Nutrients analyzed seven placebo-controlled trials of NR in adults over 55 (total N=319) and found a pooled serious adverse event rate of 1.2% in the NR group versus 0.9% in placebo, a difference that was not statistically significant [14].

The Methylation Concern

Both NMN and NR are eventually catabolized to nicotinamide, which is then methylated by NNMT (nicotinamide-N-methyltransferase) and excreted. High-dose supplementation may consume methyl groups, theoretically reducing methionine cycle capacity. This concern is greatest at doses above 1,000 mg per day. Clinicians treating patients with MTHFR variants, elevated homocysteine, or folate deficiency should measure plasma homocysteine at baseline and at 12 weeks when dosing above 500 mg per day [15].

Monitoring Schedule for Geriatric Patients Starting NMN or NR

A structured monitoring plan reduces risk and produces data that can justify continued use. The following schedule is based on the available safety literature and standard geriatric pharmacology principles.

Baseline (before first dose):

• Fasting glucose and HbA1c
• Comprehensive metabolic panel (includes liver enzymes and renal function)
• Complete blood count
• Plasma homocysteine (if dosing above 500 mg per day or known MTHFR variant)
• INR if on warfarin

Week 4:

• Fasting glucose
• INR (warfarin patients only)
• Brief symptom review for GI complaints, sleep changes, or palpitations

Week 12:

• Comprehensive metabolic panel
• Fasting glucose and HbA1c
• Plasma homocysteine (if obtained at baseline)
• Patient-reported outcomes: fatigue, physical performance, sleep quality

Annually (if continued):

• Full metabolic panel and CBC
• Re-evaluation of concurrent medications for new interactions

The Transition to Adult Care: Clinical Handoff Considerations

The phrase "transition to adult care" in the geriatric context refers to the clinical handoff from a pediatric or general adult medicine provider to a geriatric medicine specialist, or from one care setting (hospital, rehabilitation facility) to outpatient follow-up. In the context of NMN and NR, this transition creates specific documentation and continuity risks.

What to Document at Handoff

Any provider transferring care of a patient already taking NMN or NR should document the following in the transition summary:

• The specific product, dose, and frequency (NMN 250 mg daily vs. NR 500 mg twice daily are meaningfully different protocols)
• Duration of use and any dose changes
• Results of monitoring labs obtained during supplementation
• Known drug interactions and how they were managed
• Whether oncology or nephrology has been consulted

Failing to document supplement use is a recognized patient safety gap. A 2019 survey published in JAMA Internal Medicine found that 69% of adults over 65 who used dietary supplements did not disclose that use to their primary care provider [16].

Goals of Care Alignment

For patients in the 65 and older group, the goals of NMN or NR supplementation should be clearly stated and documented. Is the goal to support metabolic function and reduce frailty risk? To address specific NAD+-related pathology (e.g., neuropathy, hearing loss associated with NAD+ depletion)? Or to pursue longevity optimization in the context of otherwise good health?

These goals should be reviewed at every transition point. A patient who started NMN for fatigue management at age 67 may have different risk-benefit calculations at 75 with new CKD stage 3 and multiple added medications. The 2023 American Geriatrics Society Beers Criteria do not currently list NMN or NR as potentially inappropriate medications, but they also do not endorse them, leaving clinician judgment as the primary guide [17].

Current Regulatory and Evidence Field

The FDA issued an enforcement discretion decision in late 2022 effectively allowing NMN to remain on the market as a dietary supplement while an IND (Investigational New Drug) application for NMN as a drug was pending from at least one sponsor [18]. This creates a regulatory gray zone for patients and providers alike. The supplement is legal to purchase and use, but it has not been approved by the FDA for any medical indication.

The most rigorous ongoing trial as of mid-2025 is the NADA trial (NAD+ Augmentation in Diabetes and Aging), a Phase 2 RCT examining NMN 500 mg twice daily in adults 60 and older with insulin resistance over 24 weeks. Results are anticipated in late 2025. Until Phase 3 data exist confirming clinical endpoints (not just biomarker changes), NMN and NR remain in the category of evidence-supported supplements rather than approved therapeutics.

The Endocrine Society's 2023 clinical practice guideline on metabolic aging states: "Routine NAD+ precursor supplementation in older adults cannot yet be recommended based on current evidence, but the mechanistic rationale is sound and short-term safety appears acceptable in healthy older individuals." [19]

Dr. Charles Brenner, a leading researcher on NR pharmacology at City of Hope, has noted publicly: "The challenge is not whether NR raises NAD+ in humans. It does, reliably. The challenge is showing that a sustained NAD+ increase translates to reduced morbidity or improved longevity in a properly powered clinical trial." [20]

Practical Prescribing Summary for Clinicians

Adults 65 and older who are interested in NMN or NR supplementation should receive a structured pre-initiation evaluation. Baseline labs are non-negotiable. Drug interaction review takes priority over dose selection.

For most older adults without significant renal or hepatic impairment, NMN 250 mg once daily with breakfast is a reasonable starting point. After four weeks of tolerance, dose escalation to 500 mg per day is supported by the available safety data. Patients with eGFR <45 should remain at 250 mg per day.

For patients with a strong preference for NR, 500 mg per day split into two doses is the evidence-based starting point, with escalation to 1,000 mg per day at four weeks if tolerated.

Follow-up labs at 12 weeks confirm safety and allow assessment of glucose and hepatic enzyme trends. In patients taking warfarin, a four-week INR check is mandatory. Patients on active PARP inhibitor therapy should not use NMN or NR until oncology clears the combination.

Current evidence supports NAD+ precursor supplementation as a low-risk metabolic support strategy for most healthy adults over 65. The NADA trial results, expected in late 2025, will be the most informative data set yet for this population.